Yuemin Bian
About Yuemin Bian
Yuemin Bian is a Computational Scientist II at the Broad Institute of MIT and Harvard, specializing in machine learning applications for drug discovery. He holds a PhD in Drug Discovery and Development from the University of Pittsburgh and has extensive experience in computational chemistry and cheminformatics.
Current Role at Broad Institute
Yuemin Bian serves as a Computational Scientist II at the Broad Institute of MIT and Harvard since 2022. In this role, Bian applies machine learning techniques and in silico modeling to advance drug discovery initiatives. The Broad Institute is known for its collaborative research environment, focusing on genomic medicine and innovative approaches to understanding disease.
Previous Experience at Broad Institute
Prior to the current position, Yuemin Bian worked as a Computational Scientist I at the Broad Institute from 2020 to 2022. This role involved utilizing computational chemistry and cheminformatics to support drug discovery projects. Bian's contributions during this time helped to enhance the understanding of complex biological systems.
Educational Background
Yuemin Bian holds a Doctor of Philosophy (PhD) in Drug Discovery and Development from the University of Pittsburgh, completed from 2017 to 2020. Prior to this, Bian earned a Master's degree in Medicinal and Pharmaceutical Chemistry from the same institution, studying from 2015 to 2017. Bian also obtained a Bachelor's degree in Pharmaceutical Sciences from China Pharmaceutical University, where studies took place from 2011 to 2015.
Internship Experience
Yuemin Bian has completed several internships that contributed to professional development. In 2018, Bian worked as a Computational Chemistry Summer Intern at A2A Pharmaceuticals for three months. The following year, in 2019, Bian served as an Informatics Summer Intern at Merck in Kenilworth, NJ, also for three months. These internships provided valuable experience in the pharmaceutical industry.
Research and Expertise
Yuemin Bian specializes in integrating AI technologies with cheminformatics and computational chemistry to enhance drug discovery processes. Bian has experience in drug design and compound development, particularly targeting central nervous system disorders, cancer, and diabetes. This expertise is supported by a strong foundation in machine learning and in silico modeling techniques.